UpSMART Accelerator Programme.

In 2019 the Digital Cancer Research team within the CRUK Manchester Institute Cancer Biomarker Centre, along with our EU colleagues, including those from Fondazione IRCCS Istituto Nazionale Tumori, Milan and Vall d’Hebron, Barcelona were awarded a CRUK Accelerator Award to enable SMART Experimental Cancer Medicine Trials. The ambition of this programme, entitled “UpSMART”, is to ‘digitalise up’ experimental cancer medicine centres across the UK, Italy & Spain, providing clinical teams with digital tools for real-time access to a wealth of patient data allowing faster decision making. The UpSMART consortium consists of 23 participating centres across Experimental Cancer Medicine Centres (ECMCs) in the UK and Early Drug Development Units (EDDUs) in Spain and Italy. Furthermore, 2 collaborating centres in France have been onboarded to UpSMART and are actively involved in advancing various aspects of the programme.

The Accelerator Award funding means that the consortium can use digital healthcare products to enable data acquisition and data interpretation and create digitally enabled Phase 1 centres able to conduct technology clinical trials. The UpSMART Accelerator programme will test existing digital tools within 23 Phase 1 Units that have joined this aspiring, timely programme. UpSMART will be developing and providing all clinical sites with free to use access to new digital healthcare technology approaches and improvements in trials that enable patients access to tomorrow’s medicines today. Our goal is for these and other digital healthcare products to be shared and implemented more widely together with training in digital healthcare product approaches.

For further details on the UpSMART Accelerator Award and our ambition to drive digital innovation in early phase cancer clinical trials, please click on the link to our publication in Digital Medicine here.

The eTARGET tool has revolutionised MTB. It facilitated continued patient review during the restrictions imposed by COVID-19 and has permitted smooth transition to national MTBs. Mutation frequency data is easily accessible to all trial investigators and the addition of the trial finder tool has enabled rapid national matching to clinical trials.

Dr Donna Graham

Medical Oncologist, Digital Cancer Research team & The Christie

UpSMART Team

Professor Caroline Dive

Professor Caroline Dive

Principal Investigator

Dr Louise Carter

Dr Louise Carter

Senior Clinical Lecturer in Experimental Cancer Medicine, University of Manchester; Honorary Consultant in Medical Oncology, The Christie

Dr Donna Graham

Dr Donna Graham

Medical Oncologist, Digital Cancer Research team & The Christie

Fouziah Butt

Fouziah Butt

Principal Business Analyst, Digital Cancer Research team

Dr Elena Garralda

Dr Elena Garralda

Medical Oncologist, Co-Investigator, VHIO

Berta Colldeforns Riera

Berta Colldeforns Riera

Project Manager, VHIO

Professor Filippo de Braud

Professor Filippo de Braud

Medical Oncologist, Co-Investigator, INT

Dr Silvia Damian

Dr Silvia Damian

Medical Oncologist, INT

Andrea Villa

Andrea Villa

Project Manager, INT

Luca Agnelli

Luca Agnelli

Data Scientist, INT

Marcello Carapezza

Marcello Carapezza

IT Specialist, INT

Participating centres across Europe

Contact

11 + 15 =

Digital Cancer Research Team,

Cancer Research UK Manchester Institute

The University of Manchester

Wilmslow Road

Manchester

M20 4BX

DCR@CRUK.manchester.ac.uk

 

 

 

QUICK LINKS

Home

About

Disclaimer: The digital health products created through UpSMART are for research use only as regulatory approval has not yet been sought. Please contact us if you wish to use any of the UpSMART products in a research study.

CONTACT

Digital Cancer Research team,

Cancer Research UK Manchester Institute

The University of Manchester

Wilmslow Road

Manchester

M20 4BX

DCR@CRUK.manchester.ac.uk